Intranasal drug delivery for treatment of Alzheimer's disease

被引:54
|
作者
Fonseca, Leonor C. [1 ,2 ]
Lopes, Joao A. [1 ,2 ]
Vieira, Joao [1 ,2 ]
Viegas, Claudia [1 ,2 ]
Oliveira, Claudia S. [1 ,2 ]
Hartmann, Rafael P. [1 ,2 ]
Fonte, Pedro [1 ,2 ,3 ]
机构
[1] Univ Algarve, Ctr Marine Sci CCMar, Gambelas Campus, P-8005139 Faro, Portugal
[2] Univ Algarve, Fac Sci & Technol, Dept Chem & Pharm, Gambelas Campus, P-8005139 Faro, Portugal
[3] Univ Lisbon, IBB Inst Bioengn & Biosci, Inst Super Tecn, Dept Bioengn, P-1049001 Lisbon, Portugal
关键词
Nanoparticle; Protein; Permeation enhancer; Blood-brain barrier; Central nervous system; Neurodegenerative; AMYLOID-BETA PEPTIDE; BRAIN DELIVERY; NASAL ABSORPTION; MOUSE MODEL; NANOPARTICLES; NOSE; TRANSPORT; MEMORY; PHARMACOLOGY; MANAGEMENT;
D O I
10.1007/s13346-021-00940-7
中图分类号
TH7 [仪器、仪表];
学科分类号
0804 ; 080401 ; 081102 ;
摘要
The Alzheimer's disease is a neurodegenerative condition with severe consequences interfering with patient quality of life. It is characterized as a progressive and irreversible brain disorder hampering memory and thinking, affecting the capacity to perform daily tasks leading to physical and cognitive incapacitation. The conventional treatment occurs by the oral route, but it presents relevant drawbacks such as low bioavailability, fast metabolism, limited brain exposure, and undesirable side effects. The intranasal route has been proposed as a promising alternative to deliver drugs and improve the Alzheimer's disease treatment. Still, there is not a clear alternative delivery system available in the market with advantageous bioavailability and safety. The aim of this review is to perform an overview on the strategies for drug intranasal delivery for Alzheimer's disease treatment. The advantages and disadvantages of this delivery route and the delivery systems developed so far are discussed. A special focus is given on the use of permeation enhancers, the types of intranasal drug delivery devices, as well as possible toxicity concerns.
引用
收藏
页码:411 / 425
页数:15
相关论文
共 50 条
  • [21] Transdermal delivery of treatment for Alzheimer's disease
    Chan, Agnes L. F.
    Chien, Yie W.
    Lin, Shun Jin
    DRUGS & AGING, 2008, 25 (09) : 761 - 775
  • [22] Intranasal Delivery of a Cystatin C-peptide as Therapy for Alzheimer's Disease
    Shaw, Phyllis
    Zhang, Xu
    FASEB JOURNAL, 2013, 27
  • [23] Intranasal Delivery of Pure Nanodrug Loaded Liposomes for Alzheimer's Disease Treatment by Efficiently Regulating Microglial Polarization
    Feng, Qianhua
    Zhang, Xueli
    Zhao, Xiaowen
    Liu, Jia
    Wang, Qing
    Yao, Yuqi
    Xiao, Huifang
    Zhu, Yucui
    Zhang, Wenwen
    Wang, Lei
    SMALL, 2024, 20 (50)
  • [24] Microfluidic Synthesis of Ultrasmall Chitosan/Graphene Quantum Dots Particles for Intranasal Delivery in Alzheimer's Disease Treatment
    Mohebichamkhorami, Fariba
    Faizi, Mehrdad
    Mahmoudifard, Matin
    Hajikarim-Hamedani, Arman
    Mohseni, Seyedeh Sarvenaz
    Heidari, Amirhossein
    Ghane, Yekta
    Khoramjouy, Mona
    Khayati, Maryam
    Ghasemi, Rasoul
    Zali, Hakimeh
    Hosseinzadeh, Simzar
    Mostafavi, Ebrahim
    SMALL, 2023, 19 (40)
  • [25] Drug delivery strategies with lipid-based nanoparticles for Alzheimer's disease treatment
    Jang, Young-Ju
    Kang, Seong-Jun
    Park, Hyun Su
    Lee, Dong-Hyun
    Kim, Jae Hoon
    Kim, Ju-El
    Kim, Dong-Ik
    Chung, Chan-Hwa
    Yoon, Jeong-Kee
    Bhang, Suk Ho
    JOURNAL OF NANOBIOTECHNOLOGY, 2025, 23 (01)
  • [26] Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS
    Boado, RJ
    Tsukamoto, H
    Pardridge, WM
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 87 (11) : 1308 - 1315
  • [27] Intranasal Insulin for Alzheimer's Disease
    Hallschmid, Manfred
    CNS DRUGS, 2021, 35 (01) : 21 - 37
  • [28] Intranasal Insulin for Alzheimer’s Disease
    Manfred Hallschmid
    CNS Drugs, 2021, 35 : 21 - 37
  • [29] Drug therapy - Treatment of Alzheimer's disease
    Mayeux, R
    Sano, M
    NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (22): : 1670 - 1679
  • [30] Perspectives for drug treatment in Alzheimer's disease
    Allain, H
    Tribut, O
    Reymann, JM
    Polard, E
    Lecavorzin, P
    Bentue-Ferrer, D
    ANNALES DE MEDECINE INTERNE, 2001, 152 (08): : 527 - 532